ReviewGene therapy2006
Gene therapy progress and prospects: the skin--easily accessible, but still far away.
Review in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Barriers to Liposomal Gene Delivery: from Application Site to the Target.Iranian journal of pharmaceutical research : IJPR · 2016Review
- Human beta-defensin 3: a novel inhibitor of Staphylococcus-produced biofilm production. Commentary on "Human β-defensin 3 inhibits antibiotic-resistant Staphylococcus biofilm formation".The Journal of surgical research · 2014Article
- Ultrasound-targeted microbubble destruction enhances human β-defensin 3 activity against antibiotic-resistant Staphylococcus biofilms.Inflammation · 2013Article
- Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene.Gene therapy · 2009Article
- siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model.Gene therapy · 2009Article
- The molecular basis of human keratin disorders.Human genetics · 2009Review
- Nonviral human beta defensin-3 expression in a bioengineered human skin tissue: a therapeutic alternative for infected wounds.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyArticle
- Assessing delivery and quantifying efficacy of small interfering ribonucleic acid therapeutics in the skin using a dual-axis confocal microscope.Journal of biomedical opticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significant progress has been made in corrective gene therapy of inherited skin diseases. This includes advances in vector technology, targeted gene expression, gene replacement, and the availability of appropriate animal models for a variety of candidate diseases. In addition, an increased understanding of the uptake and trafficking mechanisms inside keratinocytes has evolved. Topical application facilitates DNA vaccination through the skin, albeit clinical benefits have not yet materialized. However, the translation into clinical trials has only been partially mastered. The latter and the control of immune responses represent challenges for the research community.
Indexed as
Identifiers
16957767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.